Quarterly Trends Report

Q3 2021: another landmark year for gene editing

  • Public Equity
  • Healthcare
  • North America

This year represents another landmark year for gene editing, with CRISPR gene editing treatment being inserted directly into the body — also known as in-vivo — becoming a reality. Third Bridge Forum spoke to several experts in Q3 2021 to gain their insights on recent developments and the competitive landscape.

As a professor at the UC Davis School of Medicine highlighted, Intellia Therapeutics released data supporting the treatment of transthyretin amyloidosis (ATTR), a disorder in which protein is deposited in organs and tissue, with the first single-dose, systemically delivered CRISPR/Cas9 therapy. “The very early clinical data… suggested that the 95% reduction in the ATTR protein that they saw in non-human primates, they’re also seeing in humans, so that’s really exciting,” they said. The US Food and Drug Administration (FDA) recently granted orphan drug designation to the treatment, NTLA-2001. As the first CRISPR therapy to edit a disease-causing gene inside the human body, the FDA said NLTA-2001 “has the potential to be the first single-dose treatment for ATTR amyloidosis”, halting and reversing its devastating complications.3

Read More

Submit your details to access the latest Quarterly Trends Report from Third Bridge.